Qi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qi Zhang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Zulong Wang
The First Affiliated Hospital of Henan University of Chinese Medicine Department of Andrology
4 shared publications - Fangyuan Li
College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, NO.37 Shi-er-qiao Road, Chengdu 610075, Sichuan Province, PR China; Hospital of Chengdu University of Traditional Chinese Medicine, NO.39 Shi-er-qiao Road, Chengdu 610075, Sichuan Province, PR China
2 shared publications Hao Zhang
Faculty of Chinese Medicine, Macau University of Science and Technology
2 shared publications- Hua Lu
Department of Orthopaedics, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Chongming Branch, Shanghai, China
2 shared publications - Rubing Chen
Department of Andrology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China
2 shared publications Shiqi Wang
The First Affiliated Hospital of Henan University of Chinese Medicine Department
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1748478
Rethinking network analysis in ethnopharmacology: a multi-omics and AI roadmap to overcome conceptual and methodological biases
Network analysis (NA) is a widely used computational tool for exploring the complex systems of interactions in ethnopharmacology, aiming to predict potential targets and generate mechanistic hypotheses. However, the predictive validity and biological relevance of its outputs are constrained by a pervasive methodological bottleneck: the recurrent identification of a narrow set of molecules—such as quercetin—across disparate natural products and diseases. Through a systematic analysis of 1,038 network-based studies, we establish “homogeneity” as a coherent, multi-level pattern, from “Flavonoid Centrality” to a “Hub-Target Core” and restricted “Canonical Pathways,” transcending specific remedies or diseases. We conceptualize this as a self-reinforcing “convergent discovery pipeline,” in which initial database biases are amplified by context-insensitive analytical approaches. Empirical evidence shows that integrating contextual experimental or multi-omics data mitigates homogeneity. To break this cycle and align network analysis more closely with pharmacological best practices, we propose an integrated framework that shifts from database dependency to empirically driven data acquisition, leverages bias-aware artificial intelligence for curation and prioritization, and advances dynamic, context-specific network modeling. This framework provides a clear roadmap to disrupt methodological inertia and steer network-based research in ethnopharmacology toward a more robust, diverse, and pharmacologically and clinically relevant future.
- 20 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1748478
Top Cited PapersOpen AccessRethinking network analysis in ethnopharmacology: a multi-omics and AI roadmap to overcome conceptual and methodological biases
Network analysis (NA) is a widely used computational tool for exploring the complex systems of interactions in ethnopharmacology, aiming to predict potential targets and generate mechanistic hypotheses. However, the predictive validity and biological relevance of its outputs are constrained by a pervasive methodological bottleneck: the recurrent identification of a narrow set of molecules—such as quercetin—across disparate natural products and diseases. Through a systematic analysis of 1,038 network-based studies, we establish “homogeneity” as a coherent, multi-level pattern, from “Flavonoid Centrality” to a “Hub-Target Core” and restricted “Canonical Pathways,” transcending specific remedies or diseases. We conceptualize this as a self-reinforcing “convergent discovery pipeline,” in which initial database biases are amplified by context-insensitive analytical approaches. Empirical evidence shows that integrating contextual experimental or multi-omics data mitigates homogeneity. To break this cycle and align network analysis more closely with pharmacological best practices, we propose an integrated framework that shifts from database dependency to empirically driven data acquisition, leverages bias-aware artificial intelligence for curation and prioritization, and advances dynamic, context-specific network modeling. This framework provides a clear roadmap to disrupt methodological inertia and steer network-based research in ethnopharmacology toward a more robust, diverse, and pharmacologically and clinically relevant future.
- Open Access
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12, 1732340
Bridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine
The ‘one-size-fits-all’ therapeutic model is inadequate to address individual patient variability, creating an urgent need for an integrative framework for precision medicine. The ‘Three Causes Tailored Treatment’ (TCTT) principle from traditional Chinese medicine offers a time-tested, holistic blueprint that simultaneously considers the individual, temporal, and environmental dimensions of health. Here, we argue that the synergy of artificial intelligence (AI) and multi-omics technologies is the key to transforming this ancient wisdom into a modern, quantitative clinical paradigm. We demonstrate how multi-omics data provides the foundational layers to quantify the TCTT principle—for instance, using integrated omics (e.g., genomics, proteomics, microbiome) to establish the individual’s molecular baseline (“Who”); chronomics to capture temporal fluxes (“When”); and the exposome to decipher the internalized environmental imprint (“Where”)—while AI-powered multimodal integration models their complex interactions. By synthesizing evidence across the disease continuum, this review provides a translational roadmap for building dynamic clinical decision-support systems, thereby charting a course toward truly personalized, time-sensitive, and context-aware healthcare.
- 18 December 2025
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 12, 1732340
Open AccessBridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine
The ‘one-size-fits-all’ therapeutic model is inadequate to address individual patient variability, creating an urgent need for an integrative framework for precision medicine. The ‘Three Causes Tailored Treatment’ (TCTT) principle from traditional Chinese medicine offers a time-tested, holistic blueprint that simultaneously considers the individual, temporal, and environmental dimensions of health. Here, we argue that the synergy of artificial intelligence (AI) and multi-omics technologies is the key to transforming this ancient wisdom into a modern, quantitative clinical paradigm. We demonstrate how multi-omics data provides the foundational layers to quantify the TCTT principle—for instance, using integrated omics (e.g., genomics, proteomics, microbiome) to establish the individual’s molecular baseline (“Who”); chronomics to capture temporal fluxes (“When”); and the exposome to decipher the internalized environmental imprint (“Where”)—while AI-powered multimodal integration models their complex interactions. By synthesizing evidence across the disease continuum, this review provides a translational roadmap for building dynamic clinical decision-support systems, thereby charting a course toward truly personalized, time-sensitive, and context-aware healthcare.
- 29 September 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (2) , 3073-3088
Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment
The progression and mechanisms of drug resistance in prostate cancer are highly complex, with the ferroptosis pathway playing a critical role. We utilized multi-omics Mendelian randomization (MR) to assess the genetic causal link between ferroptosis gene/protein expression and prostate cancer, investigating potential mediation by 731 immune cell types. Furthermore, differential expression analysis, immune infiltration analysis, single-cell RNA sequencing, gene set enrichment analysis (GSEA), and drug prediction were integrated for multidimensional validation and mechanistic insight. Our results identified cathepsin B (CTSB) as a key causal risk factor associated with iron death in the development of prostate cancer (odds ratio (OR) > 1, p < 0.01). Colocalization analysis (SNP.PP.H4 > 0.95) ruled out confounding biases. Mediation MR analysis revealed that CTSB partially mediates its carcinogenic effects by regulating various immune cells, such as PD-L1 + monocytes and CD45 + T cells (OR > 1, p < 0.05). Further analysis indicated that CTSB gene/protein expression was highly expressed in normal prostate basal epithelial cells and myeloid cells, while it was downregulated in tumor tissues and neoplastic epithelial cells (p < 0.05). Notably, its expression was positively correlated with the infiltration of multiple immune cell types (cor > 0, p < 0.05). GSEA demonstrated that high CTSB expression was significantly enriched in pro-cancer pathways, including epithelial-mesenchymal transition, angiogenesis, inflammatory response, and apoptosis (normalized enrichment score (NES) > 2, false discovery rate (FDR) < 0.001). Drug prediction analyses suggested that targeting CTSB (e.g., with bortezomib) in combination with immunotherapy may represent a novel therapeutic strategy. This study provides the first evidence of the causal role of iron death-immune interactions in prostate cancer, offering new targets for precision treatment. Graphical Abstract
- 29 September 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (2) , 3073-3088
Multi-omics genetic study revealing ferroptosis regulator CTSB driving prostate cancer progression by modulating the immune microenvironment
The progression and mechanisms of drug resistance in prostate cancer are highly complex, with the ferroptosis pathway playing a critical role. We utilized multi-omics Mendelian randomization (MR) to assess the genetic causal link between ferroptosis gene/protein expression and prostate cancer, investigating potential mediation by 731 immune cell types. Furthermore, differential expression analysis, immune infiltration analysis, single-cell RNA sequencing, gene set enrichment analysis (GSEA), and drug prediction were integrated for multidimensional validation and mechanistic insight. Our results identified cathepsin B (CTSB) as a key causal risk factor associated with iron death in the development of prostate cancer (odds ratio (OR) > 1, p < 0.01). Colocalization analysis (SNP.PP.H4 > 0.95) ruled out confounding biases. Mediation MR analysis revealed that CTSB partially mediates its carcinogenic effects by regulating various immune cells, such as PD-L1 + monocytes and CD45 + T cells (OR > 1, p < 0.05). Further analysis indicated that CTSB gene/protein expression was highly expressed in normal prostate basal epithelial cells and myeloid cells, while it was downregulated in tumor tissues and neoplastic epithelial cells (p < 0.05). Notably, its expression was positively correlated with the infiltration of multiple immune cell types (cor > 0, p < 0.05). GSEA demonstrated that high CTSB expression was significantly enriched in pro-cancer pathways, including epithelial-mesenchymal transition, angiogenesis, inflammatory response, and apoptosis (normalized enrichment score (NES) > 2, false discovery rate (FDR) < 0.001). Drug prediction analyses suggested that targeting CTSB (e.g., with bortezomib) in combination with immunotherapy may represent a novel therapeutic strategy. This study provides the first evidence of the causal role of iron death-immune interactions in prostate cancer, offering new targets for precision treatment. Graphical Abstract
- Open Access
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31226
Clinical study of Wuwei Fuzheng Yijing formula in the treatment of sperm DNA damage in male infertility: A study protocol for a randomized controlled trial
Background: The incidence of male infertility is increasing in recent years, and the semen routine examination of some patients is normal, but the semen pathological examination shows that the sperm DNA fragmentation index (DFI) is high, and the patients’ clinical manifestations are infertility or recurrent abortion of their spouses. At present, there is no special treatment for male infertility caused by high DFI, and traditional Chinese medicine compound prescription shows potential value in the treatment of male infertility. Wuwei Fuzheng Yijing formula (WFY) is an effective prescription for the treatment of sperm DNA damage in male infertility, but there is no strict clinical trial to support its application. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of WFY in patients with sperm DNA damage in male infertility. Methods: In this randomized controlled study, 100 patients who met the inclusion criteria were randomly divided into WFY group and levocarnitine oral solution group. The treatment period was 12 weeks. The main observation index was sperm DFI, and the secondary observation index was sperm concentration, motility, survival rate, and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests. All results were evaluated at the 4th and 8th week of the baseline, and the end of treatment. Discussion: This study will provide a basis for the efficacy and safety of WFY in the treatment of sperm DNA damage in male infertility with spleen and kidney qi deficiency and blood stasis.
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31226
Open AccessClinical study of Wuwei Fuzheng Yijing formula in the treatment of sperm DNA damage in male infertility: A study protocol for a randomized controlled trial
Background: The incidence of male infertility is increasing in recent years, and the semen routine examination of some patients is normal, but the semen pathological examination shows that the sperm DNA fragmentation index (DFI) is high, and the patients’ clinical manifestations are infertility or recurrent abortion of their spouses. At present, there is no special treatment for male infertility caused by high DFI, and traditional Chinese medicine compound prescription shows potential value in the treatment of male infertility. Wuwei Fuzheng Yijing formula (WFY) is an effective prescription for the treatment of sperm DNA damage in male infertility, but there is no strict clinical trial to support its application. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of WFY in patients with sperm DNA damage in male infertility. Methods: In this randomized controlled study, 100 patients who met the inclusion criteria were randomly divided into WFY group and levocarnitine oral solution group. The treatment period was 12 weeks. The main observation index was sperm DFI, and the secondary observation index was sperm concentration, motility, survival rate, and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests. All results were evaluated at the 4th and 8th week of the baseline, and the end of treatment. Discussion: This study will provide a basis for the efficacy and safety of WFY in the treatment of sperm DNA damage in male infertility with spleen and kidney qi deficiency and blood stasis.
- Open Access
- 29 March 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 108, 108670
A systematic review and meta-analysis of the association between Hashimoto's thyroiditis and ovarian reserve
- 29 March 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 108, 108670
Open AccessA systematic review and meta-analysis of the association between Hashimoto's thyroiditis and ovarian reserve
- Open Access
- 21 January 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-11
Effectiveness of electroacupuncture for thin endometrium in infertile women: study protocol for a single-blind, randomized controlled trial
Background: Thin endometrium negatively impacts the reproductive function. Current treatments for thin endometrium do not always improve endometrial receptivity. Preliminary evidence suggests that electroacupuncture could have potential therapy for thin endometrium in infertile women. Thus, this randomized controlled trial was designed to test whether electroacupuncture can improve endometrial receptivity in infertile women with thin endometrium. Methods: This study is a randomized, single-blinded, controlled, clinical trial. A total of 142 eligible patients will be recruited and randomly assigned to the electroacupuncture (EA) group or the sham electroacupuncture (SEA) group in a 1:1 ratio. Participants will receive 36 sessions over three menstrual cycles (12 weeks in total), with the same acupoint prescription. The primary outcome of this trial is endometrial thickness in the midluteal phase. The secondary outcomes include endometrial pattern, resistance index (RI) and pulsatility index (PI) of bilateral uterine artery and endometrium blood flow, serum estradiol (E2) and progesterone (P), and pregnancy rate. The pregnancy rate will be evaluated during a 6-month follow-up after completion of the trial. All other outcomes will be evaluated before treatment, during the treatment of 1st, 2nd, and 3rd menstrual cycle, and 6 months after treatment. Discussion: If the outcome confirms the effectiveness of electroacupuncture for thin endometrium in infertile women, this treatment will be proposed for application in clinical practice. Trial registration: Chinese Clinical Trials Registry ChiCTR2000029983. Registered on 18 February 2020
- 21 January 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-11
Open AccessEffectiveness of electroacupuncture for thin endometrium in infertile women: study protocol for a single-blind, randomized controlled trial
Background: Thin endometrium negatively impacts the reproductive function. Current treatments for thin endometrium do not always improve endometrial receptivity. Preliminary evidence suggests that electroacupuncture could have potential therapy for thin endometrium in infertile women. Thus, this randomized controlled trial was designed to test whether electroacupuncture can improve endometrial receptivity in infertile women with thin endometrium. Methods: This study is a randomized, single-blinded, controlled, clinical trial. A total of 142 eligible patients will be recruited and randomly assigned to the electroacupuncture (EA) group or the sham electroacupuncture (SEA) group in a 1:1 ratio. Participants will receive 36 sessions over three menstrual cycles (12 weeks in total), with the same acupoint prescription. The primary outcome of this trial is endometrial thickness in the midluteal phase. The secondary outcomes include endometrial pattern, resistance index (RI) and pulsatility index (PI) of bilateral uterine artery and endometrium blood flow, serum estradiol (E2) and progesterone (P), and pregnancy rate. The pregnancy rate will be evaluated during a 6-month follow-up after completion of the trial. All other outcomes will be evaluated before treatment, during the treatment of 1st, 2nd, and 3rd menstrual cycle, and 6 months after treatment. Discussion: If the outcome confirms the effectiveness of electroacupuncture for thin endometrium in infertile women, this treatment will be proposed for application in clinical practice. Trial registration: Chinese Clinical Trials Registry ChiCTR2000029983. Registered on 18 February 2020